"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"

NCT05299580 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped lack of enrollment

Conditions

Melanoma

Interventions

DRUG: dabrafenib
DRUG: Trametinib

Sponsor

Fondazione Melanoma Onlus